cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cyteir Therapeutics Inc
1 own
2 watching
Current Price
$1.63
$-0.01
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
57.63M
52-Week High
52-Week High
7.3121
52-Week Low
52-Week Low
1.13
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
0.00672043
P/E Ratio
P/E Ratio
41.48876292
iconMarket Capitalization57.63M
icon52-Week High7.3121
icon52-Week Low1.13
iconAverage Volume0.08M
iconDividend Yield0.00672043
iconP/E Ratio41.48876292
What does the Cyteir Therapeutics Inc do?
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Read More
How much money does Cyteir Therapeutics Inc make?
News & Events about Cyteir Therapeutics Inc.
Business Wire
8 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today presented results from a Phase 1 dose escalation monotherapy trial with CYT-0851 in a poster titled Phase 1 Results of CYT-0851 in...
Business Wire
8 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced today that Adam Veness, Esq. has joined Cyteir as General Counsel effective today. In this role, Mr. Veness will be part of...
Business Wire
9 months ago
Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a virtual R&D Day on April 26, 2022 starting at 8:30 a.m. ET. Cyteirs management will discuss the research done to...
Frequently Asked Questions
Frequently Asked Questions
What is Cyteir Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cyteir Therapeutics Inc shares?
plus_minus_icon
How can I buy Cyteir Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cyteir Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cyteir Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cyteir Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cyteir Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cyteir Therapeutics Inc?
plus_minus_icon
What percentage is Cyteir Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cyteir Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.63
$-0.01
(-0.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00